NCT04898387View on ClinicalTrials.gov

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

PHASE3CompletedINTERVENTIONAL

Enrollment

554

Participants

Timeline

Start Date

March 26, 2021

Primary Completion Date

April 13, 2023

Study Completion Date

May 30, 2023

Conditions

Ocular Hypertension Glaucoma

Interventions

COMBINATION_PRODUCT

Bimatoprost Timolol (T4030)

Eye drop

COMBINATION_PRODUCT

Bimatoprost Timolol (Ganfort)

Eye drop

Trial Locations (1)

Unknown

Medical Center Vereya EOOD, Stara Zagora

Sponsors

Lead Sponsor

Laboratoires Thea

All Listed Sponsors

lead

Laboratoires Thea

INDUSTRY